SCHEMBL17895206

SCHEMBL17895206

Nc1nc2c(C(F)(F)F)cccc2n2c(-c3ccc(O)c(O)c3)cnc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.39
USP7 Q93009 1/20 0.35
PIK3CG P48736 6/20 0.34
FYN P06241 2/20 0.33
ADORA2A P29274 3/20 0.33
ADORA1 P30542 2/20 0.33
HSD17B1 P14061 1/20 0.32
HSD17B2 P37059 1/20 0.32
ATR Q13535 1/20 0.32
ADORA3 P0DMS8 2/20 0.32
PIK3CA P42336 1/20 0.32
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
TRPA1 O75762 1/20 0.32
FGFR3 P22607 1/20 0.31
KDR P35968 1/20 0.31
MEN1 O00255 1/20 0.31
TNF P01375 1/20 0.31
CXCL8 P10145 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17895297 0.85 ADORA2A (0.43) MIFPIK3CGADORA2AADORA1ADORA3
SCHEMBL17895231 0.85 MIF (0.37) MIFFYNIKBKBCHUK
SCHEMBL17895073 0.83 IKBKB (0.41) MIFIKBKBCHUK
SCHEMBL17895194 0.81 BRD4 (0.39) IKBKBCHUK
SCHEMBL17895313 0.81 PPM1B (0.39) MIFPIK3CGADORA2AADORA1ADORA3
SCHEMBL17895108 0.81 MIF (0.39) MIFPIK3CGADORA2AADORA1PIK3CA
SCHEMBL17895268 0.80 BRD4 (0.41) IKBKBCHUK
SCHEMBL22099681 0.80 CSNK1D (0.38) MIFPIK3CGFYNPIK3CAMEN1
SCHEMBL17895242 0.78 ADORA2A (0.45) MIFADORA2AADORA1ADORA3IKBKB
SCHEMBL17895232 0.77 ADORA2A (0.37) MIFUSP7ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP claimed
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP claimed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO claimed
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP disclosed
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer UNIVERSITE DE MONTPELLIER (FR) 2020-06-23 US disclosed
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP disclosed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer NQO1, NQO2, ABL1 MIF 3073/4885USP7 3624/4885PIK3CG 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.